DelveInsight added a report on the “Myocarditis Market“. It covers an overview, its causes, signs and symptoms, and therapies. Major players are involved in developing therapies for Myocarditis. The launch of emerging therapies will significantly impact the Myocarditis market.
Myocarditis Overview
Myocarditis is a disease that causes inflammation of the heart muscle. This inflammation enlarges and weakens the heart, creates scar tissue, and forces it to work harder to circulate blood and oxygen throughout the body. The inflammation can lead to arrhythmias, cardiomyopathy, or heart failure. Viral infections are a leading cause of myocarditis.
Some of the key highlights of the Myocarditis Market Report
- Myocarditis is slightly predominant in men.
- Estimates that approximately 1–5% of patients that test positive for acute viral infection(s) may exhibit a form of myocarditis.
- Lymphocytic myocarditis was recorded in 1.06% of 12,747 unselected routine autopsies performed over a 10-year period. Dilated cardiomyopathy (DCM) has an estimated frequency of 7.5%–10% per 100,000 inhabitants per year.
- Myocarditis companies included such as Cardiol Therapeutics, Kiniksa Pharmaceuticals, and others.
- Myocarditis drugs included such as Rilonacept, CardiolRx, and others.
Get a sample copy of the report @ Myocarditis Market Share
Myocarditis Symptoms
The symptoms of myocarditis are not specific to the disease and are similar to symptoms of more common heart disorders. A sensation of tightness or squeezing in the chest that is present with rest or exertion is common. In a majority of cases, the symptoms of myocarditis are preceded a few days to weeks by a flu-like illness.
Myocarditis Diagnosis
The diagnosis is usually made based on clinical presentation and noninvasive imaging findings. Most patients respond well to standard heart failure therapy, although in severe cases, mechanical circulatory support or heart transplantation is indicated. Prognosis in acute myocarditis is generally good except in patients with giant cell myocarditis. Persistent, chronic myocarditis usually has a progressive course but may respond to immunosuppression.
Myocarditis treatment depends on the cause and severity. For example, people with only mild viral myocarditis may be allowed to rest at home. They will be advised not to smoke or to drink alcohol. People with myocarditis that causes heart failure symptoms or irregular heartbeat (cardiac arrhythmias) will be treated in a hospital. Currently, there is no cure for myocarditis and the goal of medical therapy is to support the heart function so that adequate blood circulation is maintained.
Do you know about Myocarditis Market Size?
Myocarditis Market Insights
Myocarditis that presents with heart failure symptoms and decreased heart pump function can be treated according to the current national society guidelines for “systolic” heart failure. Therapeutic molecules that block the immune system are generally not indicated for the management of the most common forms of myocarditis in adults. However, in specific forms of myocarditis, such as giant cell myocarditis, cardiac sarcoidosis or eosinophilic myocarditis, medications that modify the immune response can be considered. Non-steroidal anti-inflammatory drugs, such as ibuprofen can be avoided due to a risk of increased inflammation.
Myocarditis Therapeutics
In patients with severe myocarditis and symptomatic hypotension, parenteral inotropes, including phosphodiesterase inhibitors (e.g., milrinone) or adrenergic agonists (e.g., dobutamine or dopamine) may be required. Severe myocarditis patients’ develop low blood pressure despite optimal medical care. These patients may require a temporary heart pump (a kind of mechanical circulatory support device) to survive the acute injury. Some of these patients with myocarditis can be bridged to recovery and have the pump removed. The survival after heart transplantation for adult patients with myocarditis is similar to that for other causes of cardiac failure.
Myocarditis Emerging Therapy
The available therapeutics treatment options in Myocarditis landscape aim to reduce the complications for subjects with Myocarditis. The dynamics of Myocarditis market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies and incremental healthcare spending across the world. The launch of emerging therapies is expected during the forecast period of 2020–2030.
Download sample report @ Myocarditis Market Research Report
Table of content
1. Key Insights
2. Myocarditis: Market Overview at a Glance
3. Executive Summary
4. Organizations
5. Disease Overview: Myocarditis
7. 7MM Epidemiology of Myocarditis
8. Treatment and Management
9. Unmet Needs
10. Key Cross Competition
11. Myocarditis: 7 Major Market Analysis
12. Market Outlook: 7MM
13. Market Drivers
14. Market Barriers
15. Market Access
16. SWOT Analysis
17. Case Studies
18. KOL views
19. Bibliography
20. Appendix
21. Report Methodology
22. DelveInsight Capabilities
23. Disclaimer
24. About DelveInsight
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
